Table 4.

Logistic regression evaluating the impact of different variables on the incidence of QTc prolongation

Variable	OR (95% CI)	P value
Age	1.02 (0.99–1.06)	0.14
Male	1.34 (0.48–3.75)	0.56
BMI	0.94 (0.86–1.02)	0.17
CrCl (< 60 mL/min)	1.01 (1.0-1.02)	0.044
Atrial fibrillation	0.42 (0.02–6.32)	0.53
Bundle branch block	3.10 (0.24–39.37)	0.38
Has a pacemaker	3.30 (0.30-35.45)	0.32
Psychological disorders	1.18(0.40–3.52)	0.75
Coronary artery disease	1.10 (0.20–5.95)	0.90
Drug abuse	0.60 (0.11–3.11)	0.55
Cannabis use	0.90 (0.25–3.19)	0.87
Alcohol abuse	2.32 (0.59–9.11)	0.22
Has a risk factor for QTc prolongation	2.01 (0.69–5.85)	0.19
Baseline QTc	1.00 (0.98–1.01)	0.709
Cumulative droperidol dose	1.27 (1.04–1.56)	0.019
QTc-prolonging medications before droperidol	1.65 (0.62–4.35)	0.312
QTc-prolonging medications after droperidol	1.65 (0.51–5.30)	0.396

Abbreviations: BMI, body mass index; CrCl, creatinine clearance